Device Trial Radar · NCT05077644
Mobile Application in the Management of Mild to Moderate Postpartum Depression (PPD)
Last checked: Nov 20, 2026Latest source record: Oct 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
65
Planned (sponsor's estimate)
Start
Oct 1, 2021
Primary completion
Dec 31, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Curio Digital Therapeutics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 14, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective: Evaluate the user experience with the Stella (TM) app for the management of Postpartum Depression in an observed population for 8 calendar weeks.
Conditions
- Post-partum Depression
Interventions
Stella (TM) Mobile ApplicationDevice
Treatment of mild-to-moderate postpartum depression (PPD) using Cognitive Behavioral Therapy techniques.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in level of depression as measured by Edinburgh Postpartum Depression (EPDS)Time frame: 8 week period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
HITLAB
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.